Yes. Royalty Pharma was formerly owned by 4 private investors.
Royalty Pharma is headquartered in New York, New York.
Royalty Pharma disclosed revenue of 2,264M USD for 2024 and 2,354M USD for 2023.
Royalty Pharma is a business services company.
Royalty Pharma was founded in 1996.
110 East 59th Street,
New York, New York
10022
United States,
(212) 883-0200
www.royaltypharma.com
Royalty Pharma is a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals, and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and three development-stage product candidates. Royalty Pharma was formed in 1996 and is based in New York, New York.
| Year | ≤ '20 | '21 | '22 | '23 | '24 | '25 | T | |
|---|---|---|---|---|---|---|---|---|
| Buy (0.2/yr) | # | 2 | 1 | - | - | - | - | 3 |
| vol | $3.1B | $240M | $3.4B | |||||
| Sell (0.0/yr) | # | - | - | - | - | - | - | 0 |
| 3 | ||||||||
| Legal | Deals |
|---|---|
|
Jones Day |
2 |
|
Gibson, Dunn & Crutcher |
1 |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
